We're thrilled to share our latest research on human placental mesenchymal stem cells (hPMSCs) and their derived extracellular vesicles (EVs) as a potential therapy for acute respiratory distress syndrome (ARDS)! This important work highlights the promising role of placental MSCs and their EVs in ameliorating lung injury and improving outcomes in ARDS. Our study, published in the journal MDPI Cells, demonstrates that hPMSCs and EVs effectively reduce inflammation and tissue damage in a murine model of ARDS. These findings pave the way for further investigation into the potential of hPMSCs and EVs as a novel therapeutic approach for ARDS patients. ARDS is a devastating respiratory condition with limited treatment options. The development of effective therapies is crucial for improving patient survival and quality of life. We are excited about the potential of hPMSCs and EVs to revolutionize ARDS treatment. Our research is a significant step towards this goal, and we are committed to continuing our efforts to bring this promising therapy to patients. Read our full article here: https://lnkd.in/d6RWEjA5 #ards #stemcells #inflammation #exosomes #covid19 #advancedtherapies Cells MDPI; KELI Therapeutics; Lietuvos sveikatos mokslų universitetas (LSMU)
